Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gilbert

Showing results (811-820 of 869) with videos related to

Pageof 87
Sort By:
BMJ (Clinical Research Ed.)|July 9, 2024
Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaborationAnthony Muchai Manyara, Philippa Davies, Derek Stewart, et al.
The Journal of Clinical Investigation|August 9, 2014
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S Li, Peter B Gilbert, Georgia D Tomaras, et al.
Eclinicalmedicine|October 25, 2023
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trialsOriana Ciani, Anthony M Manyara, Philippa Davies, et al.
Nature Communications|May 25, 2026
Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infectionJames I Mullins, Wenjie Deng, Elena E Giorgi, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy IndividualsNathan B Erdmann, Wilton B Williams, Stephen R Walsh, et al.
Nature Medicine|March 2, 2011
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trialMorgane Rolland, Sodsai Tovanabutra, Allan C deCamp, et al.
Science Translational Medicine|September 20, 2019
Immune correlates of the Thai RV144 HIV vaccine regimen in South AfricaGlenda E Gray, Ying Huang, Nicole Grunenberg, et al.
Ebiomedicine|June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling studyYunda Huang, Lily Zhang, Huub Gelderblom, et al.
The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
Vaccine|June 29, 2023
Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trialsChristine B Turley, LaKesha Tables, Trevon Fuller, et al.
Pageof 87

Showing results (811-820 of 869) with videos related to

Sort By:
Pageof 87
BMJ (Clinical Research Ed.)|July 9, 2024
Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaborationAnthony Muchai Manyara, Philippa Davies, Derek Stewart, et al.
The Journal of Clinical Investigation|August 9, 2014
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S Li, Peter B Gilbert, Georgia D Tomaras, et al.
Eclinicalmedicine|October 25, 2023
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trialsOriana Ciani, Anthony M Manyara, Philippa Davies, et al.
Nature Communications|May 25, 2026
Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infectionJames I Mullins, Wenjie Deng, Elena E Giorgi, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy IndividualsNathan B Erdmann, Wilton B Williams, Stephen R Walsh, et al.
Nature Medicine|March 2, 2011
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trialMorgane Rolland, Sodsai Tovanabutra, Allan C deCamp, et al.
Science Translational Medicine|September 20, 2019
Immune correlates of the Thai RV144 HIV vaccine regimen in South AfricaGlenda E Gray, Ying Huang, Nicole Grunenberg, et al.
Ebiomedicine|June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling studyYunda Huang, Lily Zhang, Huub Gelderblom, et al.
The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
Vaccine|June 29, 2023
Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trialsChristine B Turley, LaKesha Tables, Trevon Fuller, et al.
Pageof 87